Loading clinical trials...
Loading clinical trials...
A Single Center, Randomized Controlled, Open Label Trial to Explore the Regulatory Effect of Belimumab on Antibody Titers in Primary Antiphospholipid Syndrome Patients Carrying Medium to High Titers of Antiphospholipid Antibodies
Conditions
Interventions
Belimumab+SOC
SOC
Locations
1
China
Ruijin Hospital
Shanghai, Shanghai Municipality, China
Start Date
April 1, 2024
Primary Completion Date
May 31, 2026
Completion Date
May 31, 2027
Last Updated
December 24, 2024
NCT07372170
NCT06978647
NCT06371417
NCT07108023
NCT06884384
NCT06929182
Lead Sponsor
Ruijin Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions